📋 Tender Overview
An Innovative Implantable Device And Management Platform To Prevent Chronic Fluid Congestion
Objective
Pathologic fluid overload is a main clinical complication of congestive heart failure (CHF). CHF is a severe chronic disease affecting ~28 M people worldwide. Around 8 M of CHF patients are resistant to oral medications and undergo frequent hospitalizations to remove extra fluids with aggressive acute treatments, all carrying severe complications. None of these treatments can prevent fluid accumulation. The Israeli SME Paragate Medical has developed FILBERT, a unique implantable peritoneal ultrafiltration system for diuretic resistant CHF patients. It enables 24/7 monitoring and gentle draining of extra fluids in the urinary system, preventing their accumulation. A remote treatment management platform allows physicians to continuously control patients’ conditions and timely adjust therapy to prevent fluid accumulation. FILBERT shifts the paradigm of fluid congestion care from the hospital to the home, improving patients’ quality of life and saving billions to healthcare systems.
Funded Under
The European Innovation Council (Eic)
Total Cost
€ 12 651 755,00
Eu Contribution
€ 2 500 000,00
Coordinated By
Paragate Medical Ltd
Israel
